Vivos Therapeutics, Inc. (VVOS) Tops Q3 EPS by 88c

Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q3 EPS of ($1.75), $0.88 better than the analyst estimate of ($2.63). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $4.69 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Hyperscale Data signs $1.2B AI compute deal for Michigan campus
• Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity